Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
BörsenkürzelXCUR
Name des UnternehmensExicure Inc
IPO-datumMay 09, 2018
CEOMr. Paul Kang
Anzahl der mitarbeiter7
WertpapierartOrdinary Share
GeschäftsjahresendeMay 09
Addresse2430 N. Halsted St.
StadtCHICAGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl60614
Telefon18476731707
Websitehttps://www.exicuretx.com/
BörsenkürzelXCUR
IPO-datumMay 09, 2018
CEOMr. Paul Kang
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten